“…Recent studies have proposed that YKL‐40 plays a prominent role in cell proliferation, differentiation, angiogenesis, tissue remodeling, inflammation, and antiapoptosis (Johansen et al, 2007; Johansen et al, 2009; Kazakova & Sarafian, 2009). Other studies also found that YKL‐40 was associated with the prognosis of EC patients, and the increased levels of YKL‐40 in EC predicted poor clinical outcomes, which also influenced the proliferative, migratory, invasive, and antiapoptotic ability of HEC‐1A cells (Kotowicz et al, 2017; Lili Li et al, 2018). However, the molecular mechanisms for YKL‐40 in EC are not yet clear.…”